Sanofi releases its half-year 2026 financial report and updates on business growth and pipeline progress.

Sanofi has published its half-year financial report for the period ending June 30, 2026, available on its website and filed with regulatory authorities in France and the US. The report highlights Sanofi's strong business performance, including double-digit sales growth and an upgraded 2026 guidance. Additionally, Sanofi announced the discontinuation of clinical development for amlitelimab in atopic dermatitis, reflecting a strategic pipeline adjustment. These updates demonstrate Sanofi's commitment to innovation and growth in the biopharma sector.